Although anti-PD-1/PD-L1 therapy changes the tumor microenvironment by increasing the infiltrating CD8 T cells with cytotoxic activity [30,101] and can improve CD8 T cell primming by dendritic cells [102], these effects could be temporary due to the induction of compensatory inhibitory pathways [60]. The gene discussed is CD8A; the disease is neoplasm.